More articles from Volume 52, Issue 1, 2023
SYNCOPA IN CHILDREN AND ADOLESCENTS OUR EXPERIENCE
ONE-DAY THYROID SURGERY - POSSIBILITIES AND LIMITATIONS
DEMOGRAPHIC AND CLINICAL VARIATIONS IN THE OCCURRENCE OF PEPTIC ULCER - TRENDS OVER A TEN-YEAR PERIOD
KAWASAKI DISEASE
PARANEOPLASTIC PEMPHIGUS ASSOCIATED WITH NON-HODGKIN'S LYMPHOMA: A CASE REPORT
KAWASAKI DISEASE
Published: 01.11.2024.
Volume 52, Issue 1 (2023)
pp. 17-22;
Abstract
Kawasaki disease (KD) is an acute, self-limited vasculitis of unknown etiology that occurs predominantly in children under the age of 5 years. In addition to the progress of modern medicine, the cause of KD is currently unknown and specific diagnostic tests for definitive diagnosis does not exist. The differential-diagnostic enigma is the exclusion of other diseases with similar clinical features. The primary treatment in the acute phase of KD is intravenous immunoglobulin (IVIG) and acetylsalicylic acid (ASA/aspirin). There is not a recommendation to a uniform therapeutic approach in refractory KD. The role of corticosteroids is still controversial, but there are studies that support its use as adjuvant treatment. Most patients have a good prognosis. The focus of future research should be the formulation of new algorithms for detection, differential diagnostic triage and treatment of KD.
Keywords
References
1.
Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Vol. 16, *Arerugi Allergy*. p. 178–222.
2.
Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Vol. 130, *Am J Dis Child*. p. 599–607.
3.
Kosaki F, Kawasaki T, Okawa S. Clinicopathological conference on 10 fatal cases with acute febrile mucocutaneous lymph node syndrome. Vol. 24, *Shonika Rinsho (Jpn J Pediatr)*. p. 2545–9.
4.
Cannon L, Campbell MJ, Wu EY. Multisystem inflammatory syndrome in children and Kawasaki disease: Parallels in pathogenesis and treatment. Vol. 23, *Curr Allergy Asthma Rep*. p. 341–50.
5.
Anđelić S. *ABCDE u urgentnoj medicini*.
6.
Milutinović-Puača J, Anđelić S. The frequency of heart rhythm disorders in the prehospital phase of acute coronary syndrome. Vols. 4-ENG):15-21, *Russian Journal of Cardiology*.
7.
Victor S, McKillion KC, Puette JA, McKillion P, Ellison MB. Unexpected evolution after multivessel coronary artery bypass grafting in a patient with Kawasaki disease. Vol. 13, *Cureus*.
8.
Kim GB. Reality of Kawasaki disease epidemiology. Vol. 62, *Korean J Pediatr*. p. 292–6.
9.
Okazaki K, Matsui K, Takahashi N, Miura M, Kondo M. Kawasaki disease in a preterm neonate: case report and cytokine profile. Vol. 60, *Pediatr Int*. p. 1037–9.
10.
O’Connor T, McNally C, Kennedy MW. Adult Kawasaki disease: a rare and challenging diagnosis – a case report. Vol. 7, *European Heart Journal - Case Reports*. p. 1–5.
11.
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Vol. 135, *Circulation*. p. 28356445.
12.
Lee JK. Hygiene Hypothesis as the etiology of Kawasaki disease: Dysregulation of early B cell development. Vol. 22, *Int J Mol Sci*.
13.
Todorović G, Joldžić A, Anđelić S, Nedeljković D. Transmisija virusa SARS-COV-2 u porodici. Vol. 26, *Halo. p. 143–8.
14.
Janić D. Kavasakijeva bolest. Vol. 2, *Scripta Pediatrica*. p. 27–33.
15.
Mohankumar SP, Das S, Likitha P, Naranje P, Jana M, Gupra SK, et al. Kawasaki disease or polyarteritis nodosa: coronary involvement, a diagnostic conundrum. Vol. 43, *Rheumatology International*. p. 2327–31.
16.
M NR, M A. Kawasaki disease: pathophysiology and insights from mouse models. Vol. 16, *Nat Rev Rheumatol*. p. 391–405.
17.
Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Vol. 43, *Japanese Circulation Journal*. p. 633–43.
18.
Lindquist ME, Hicar MD. B cells and antibodies in Kawasaki disease. Vol. 20, *Int J Mol Sci*.
19.
Rife E, Gedalia A. Kawasaki disease: an update. Vol. 22, *Curr Rheumatol Rep*.
20.
Soni PR, Noval Rivas M, Arditi M. Comprehensive update on Kawasaki disease vasculitis and myocarditis. Vol. 22, *Curr Rheumatol Rep*.
21.
Emiš-Vandlik N, Anđelić S, Čolaković G, Bogunović S. Infarkt miokarda bez opstrukcije koronarnih arterija (MINOCA. Vol. 25, *Halo. p. 165–72.
22.
Kuo HC. Diagnosis, progress, and treatment update of Kawasaki disease. Vol. 24, *Int J Mol Sci*.
23.
Pilania RK, Singh S. Kawasaki disease. Vol. 30, *Periodic and Non-Periodic Fevers*. p. 45–63.
24.
Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Vol. 84, *Circ J*. p. 1348–407.
25.
Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, et al. Revision of diagnostic guidelines for Kawasaki disease. Vol. 62, *Pediatr Int*. p. 1135–8.
26.
Owens AM, disease PMCK.
27.
Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al. Japanese Circulation Society Joint Working Group. Vol. 2020;84(8):1348-1407, JCS/JSCS.
28.
Park WY, Lee SY, Kim GB, Song MK, Kwon HW, Bae EJ, et al. Clinical aspects for differential diagnosis of Kawasaki disease shock syndrome: a case control study. Vol. 21, *BMC Pediatr*.
29.
Lj R, O M, M V, R S, M B. Atypical Kawasaki disease. Vol. 69, *Med Pregl*. p. 53–7.
30.
Stefanović I, Sinđelić V, Anđelić S, Tasić-Uroš D, Milivojčević Bevc I, Čolaković G. Zaživotno neprepoznat miokarditis kao uzrok iznenadne srčane smrti radnika dostave hrane. Vol. 194*. 29, *Halo.
31.
32.
Robinson C, Chanchlani R, Gayowsky A, Darling E, Seow H, Batthish M. Health care utilization and costs following Kawasaki disease. Vol. 27, *Paediatr Child Health*. p. 160–8.
33.
Marchesi A, Rigante D, Cimaz R, Ravelli A, Jacobis IT, Rimini A, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Vol. 47, *Ital J Pediatr*.
34.
Zhu F, Ang JY. update on the clinical management and diagnosis of Kawasaki disease. Vol. 23, *Curr Infect Dis Rep*.
35.
Gringani R, Quek SC. Kawasaki disease in 2019 - past, present insights and future direction: a narrative review. Vol. 2, *Pediatr Med*.
36.
Nadig PL, Joshi V, Pilania RK, Kumrah R, Kabeerdoss J, Sharma S, et al. Intravenous immunoglobulin in Kawasaki disease – evolution and pathogenic mechanisms. Vol. 13, *Diagnostics*.
37.
Miura M, Ayusawa M, Fukazawa R, Hamada H, Ikeda S, Ito S, et al. Guidelines for medical treatment of acute Kawasaki disease. Vol. 2021;5(1):41–73.
38.
Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Vol. 9, *Front Immunol*.
39.
Kwon JE, Roh DE, Kim YH. The impact of moderate-dose acetylsalicylic acid in the reduction of inflammatory cytokine and prevention of complications in the acute phase of Kawasaki disease: The benefit of moderate-dose acetylsalicylic acid. Vol. 7, *Children*.
40.
Matsumoto K, Hasegawa S, Nakao S, Shimada K, Mukai R, Tanaka M, et al. Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration adverse event reporting system and the Japanese adverse drug event report databases using disproportionality analysis. Vol. 8, *SAGE Open Med*.
41.
Kim GB, Yu JJ, Yoon KL, Jeong SI, Song YH, Han JW, et al. Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes. Vol. 184, *J Pediatr*. p. 125–9.
42.
Jia X, Du X, Bie S, Li X, Bao Y, Jiang M. What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis. In: *Rheumatology. p. 1826–33.
43.
Tanoshima R, Hashimoto R, Suzuki T, Ishiguro A, Kobayashi T. Effectiveness of antiplatelet therapy for Kawasaki disease: A systematic review. Vol. 178, *Eur J Pediatr*. p. 947–55.
44.
Huang YH, Hsin YC, Wang LJ, Feng WL, Guo MMH, Chang LS, et al. Treatment of Kawasaki disease: A network meta-analysis of four dosage regimens of aspirin combined with recommended intravenous immunoglobulin. Vol. 12, *Front Pharmacol*.
45.
Duignan S, Doyle SL, McMahon CJ. Refractory Kawasaki disease: diagnostic and management challenges. Vol. 10, *Pediatr Health Med Ther*. p. 131–9.
46.
Aslani N, Raeeskarami S, Aghaei-Moghadam E, Tahghighi F, Assari R, Sadeghi P, et al. Intravenous methylprednisolone pulse therapy versus intravenous immunoglobulin in the prevention of coronary artery disease in children with Kawasaki disease: A randomized controlled trial. Vol. 14, *Cureus*.
47.
Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Vol. 27, *Cochrane Database Syst Rev*.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
